Breast implants seller Sientra debuts IPO

Santa Barbara, Calif-based Sientra, a seller of breast implants, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “SIEN.” Piper Jaffray and Stifel are serving as lead underwriters. Sientra’s backers include OrbiMed Advisors, Clarus Ventures, Abingworth Management, Goldman Sachs and TIAA-CREF.


European venture capital rebounds in fourth quarter

The European venture capital business rebounded in the fourth quarter with fundraising and IPOs up and investments to startups growing at a smart pace, too. Twenty-three venture funds raised nearly $2 billion in the quarter, the most money raised in a quarter in two years, and eight IPOs of venture-funded European companies took place.

Valeritas Lands $150M Series C

Valeritas Inc., a Bridgewater, N.J.-based developer of drug delivery systems for the diabetes market, has raised $150 million in Series C financing. The funding will support commercialization of its V-Go disposable insulin delivery device. Welsh, Carson, Anderson & Stowe led the financing and assumes a controlling interest in Valeritas. Previous investors MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, ONSET Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures also participated.

Magellan Biosci Navigates TREK Diagnostics Sale to Strategic

Magellan Biosciences, the Boston-based diagnostics company, sold its TREK Diagnostic Systems, the company’s microbiology business, to strategic acquirer Thermo Fisher Scientific. Terms of the deal were not publicized. Backers of Magellan include Abingworth Management, Hambrecht & Quist Capital Management, KBL Healthcare Ventures, Ampersand Ventures, New England Partners Capital LP, Nexus Medical Partners II SICAR, and Boston Community Venture Fund.

Biotie Buys VC-Backed Synosia Therapeutics

Biotie, a Finland-based drug development company, has agreed to pay 93.6 million euros ($127 million) for Switzerland-based biotherapeutics company Synosia Therapeutics, providing an exit for a slew of venture investors. 5AM Ventures, Aravis SA, Investor Growth Capital, Novo A/S, Swiss Helvetia Fund, UCB S.A., Versant Venture Management and Abingworth Management had backed Synosia.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget